Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 3976 AL 3990

Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease

Tropea TF, Chen-Plotkin AS.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1(Suppl 1):S15-S18. doi: 10.1016/j.parkreldis.2017.07.021. Epub 2017 Jul 22.

Atypical parkinsonian syndromes: a general neurologist's perspective

Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK.

Eur J Neurol. 2018 Jan;25(1):41-58. doi: 10.1111/ene.13412. Epub 2017 Sep 28.

Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma

Drapalo K, Jozwiak J.

Int J Neurosci. 2018 Feb;128(2):167-174. doi: 10.1080/00207454.2017.1366906. Epub 2017 Aug 28.

[Driving ability in Parkinson's disease]

Buhmann C, Vesper J, Oelsner H.

Fortschr Neurol Psychiatr. 2018 Jan;86(1):43-48. doi: 10.1055/s-0043-110051. Epub 2017 Aug 15.

The rise and fall of impulse control behavior disorders

Cossu G, Rinaldi R, Colosimo C.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S24-S29. doi: 10.1016/j.parkreldis.2017.07.030. Epub 2017 Aug 1.

Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds

de Los Rios C, Cano-Abad MF, Villarroya M, López MG.

Pflugers Arch. 2018 Jan;470(1):187-198. doi: 10.1007/s00424-017-2044-5. Epub 2017 Aug 19.

Cognitive dysfunction and symptoms of movement disorders in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Ikeuchi T, Mezaki N, Miura T.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S39-S41. doi: 10.1016/j.parkreldis.2017.08.018. Epub 2017 Aug 16.

Cognitive complaint in early Parkinson's disease: A pilot study

Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.

Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22.

Postmortem studies of deep brain stimulation for Parkinson's disease: a systematic review of the literature

Reddy GD, Lozano AM.

Cell Tissue Res. 2018 Jul;373(1):287-295. doi: 10.1007/s00441-017-2672-2. Epub 2017 Aug 23.

Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections

Cardoso F.

Toxicon. 2018 Jun 1;147:107-110. doi: 10.1016/j.toxicon.2017.08.018. Epub 2017 Aug 23.

Mitochondrial calcium imbalance in Parkinson's disease

Ludtmann MHR, Abramov AY.

Neurosci Lett. 2018 Jan 10;663:86-90. doi: 10.1016/j.neulet.2017.08.044. Epub 2017 Aug 26.

From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue

Tucker D, Lu Y, Zhang Q.

Mol Neurobiol. 2018 Jun;55(6):5137-5153. doi: 10.1007/s12035-017-0712-2. Epub 2017 Aug 24.

Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies

Brodowicz J, Przegaliński E, Müller CP, Filip M.

Neurotox Res. 2018 Feb;33(2):474-484. doi: 10.1007/s12640-017-9798-6. Epub 2017 Aug 25.

How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology

Borghammer P.

Mov Disord. 2018 Jan;33(1):48-57. doi: 10.1002/mds.27138. Epub 2017 Aug 26.

Striatal synapses, circuits, and Parkinson's disease

Zhai S, Tanimura A, Graves SM, Shen W, Surmeier DJ.

Curr Opin Neurobiol. 2018 Feb;48:9-16. doi: 10.1016/j.conb.2017.08.004. Epub 2017 Aug 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias